Clinical Manual for Management of the HIV-Infected ... - myCME.com

More documents

Recommendations

Info

Lymphadenopathy Background Lymphadenopathy is very common in HIV-infected individuals and may occur at any stage of HIV infection. It may be the first indication of a serious local or systemic condition, and should be evaluated carefully. Rapid enlargement of a previously stable lymph node or a group of nodes requires evaluation to identify the cause and to determine whether treatment is needed. Similarly, nodes that are abnormal in consistency, tender to palpation, fluctuant, asymmetrical, adherent to surrounding tissues, or accompanied by other symptoms should be evaluated promptly. Lymphadenopathy may be generalized or localized and is usually characterized by lymph nodes that are >1 cm in diameter. A multitude of conditions can cause lymphadenopathy, including HIV itself, opportunistic or other infections, and malignancies. The likely causes of lymphadenopathy, and thus the diagnostic workup, will depend in part on the patient’s degree of immunosuppression. The risk of opportunistic and certain malignant conditions increases at lower CD4 cell counts (see chapter CD4 Monitoring and Viral Load Testing). Many individuals with primary HIV infection (see chapter Primary HIV Infection) may have generalized lymphadenopathy that may resolve or may persist for months to years. If lymphadenopathy of >2 cm in size occurs in 2 or more noncontiguous sites and persists for more than 3 months, and if appropriate evaluation reveals no other cause, the patient is diagnosed with persistent generalized lymphadenopathy (PGL). PGL is usually due to follicular hyperplasia from chronic HIV infection. As long as enlarged nodes are stable in number, location, and size, persons with PGL require no management other than monitoring of nodes at each physical examination. Changes in the character of the lymph nodes should prompt further evaluation. Rapid involution of PGL may occur with advanced HIV disease and is a poor prognostic sign. S: Subjective Section 5—Complaint-Specific Workups | 5–29 The patient complains of new, worsening, or persistent glandular swellings in the neck, axilla, groin, or elsewhere. Ascertain the following during the history: ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ Symptoms that accompany the lymphadenopathy, particularly constitutional symptoms such as fever, sweats, fatigue, and unintentional weight loss. Localized symptoms or conditions that involve areas of the body with lymphatic drainage into the area of abnormal lymph nodes (eg, in the case of axillary lymphadenopathy, ask about breast masses and skin conditions or trauma involving the arm) A full review of systems HIV-related or other malignancies, opportunistic illnesses Recent travel, country or region of origin, disease exposures (eg, tuberculosis [TB], sexually transmitted infections), and risk behaviors (eg, injection drug use) Trauma or injury (including cat scratches) Exposure to household pets Current medications Review recent CD4 cell counts and HIV viral load measurements. O: Objective Check vital signs. Perform a complete examination of lymph nodes, including the cervical, submandibular, supraclavicular, axillary, epitrochlear, and inguinal sites. Document the location, size, consistency, mobility, and presence or absence of tenderness of all abnormal nodes. In cases of localized lymphadenopathy, examine the area drained by the node. Check for hepatosplenomegaly. Perform a focused examination (eg, lung, breast, skin, genitals) to identify signs of local or systemic illness.
5–30 | Clinical Manual for Management of the HIV-Infected Adult/2006 A: Assessment The differential diagnosis of lymphadenopathy in HIV-infected patients depends in part on the degree of immunosuppression. For further information, see chapter CD4 Monitoring and Viral Load Testing. Infectious Causes Generalized lymphadenopathy ♦ HIV infection, including PGL ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ Mononucleosis; Epstein-Barr virus Mycobacterium avium complex TB Cytomegalovirus Secondary syphilis Toxoplasmosis Histoplasmosis, other fungal diseases Bartonella infection Hepatitis B Lyme disease Chlamydia (Lymphogranuloma venereum [LGV]) Widespread skin infections Immune reconstitution syndrome Follicular hyperplasia Localized lymphadenopathy ♦ Any of the above ♦ ♦ ♦ ♦ Oropharyngeal and dental infections Cellulitis or abscesses Chancroid TB (scrofula) Neoplastic causes ♦ Lymphoma ♦ ♦ ♦ Acute and chronic lymphocytic leukemias Other malignancy; metastatic cancer Kaposi sarcoma Other causes ♦ Reactive process (benign) ♦ ♦ ♦ ♦ ♦ Sarcoidosis Hypersensitivity reaction to medications Serum sickness Rheumatoid arthritis Castleman disease P: Plan Diagnostic Evaluation After the history and physical examination, the cause of lymphadenopathy may be clear and further diagnostic testing may not be necessary. If the cause of the lymphadenopathy is still uncertain, perform diagnostic testing as indicated by the patient’s presentation. This may include the following tests: ♦ ♦ ♦ ♦ ♦ ♦ ♦ CD4 count (with or without HIV viral load), to determine the risk of opportunistic illnesses Complete blood count with differential; liver function tests; urinalysis Chest x-ray Tuberculin skin test (purified protein derivative, or PPD) Rapid plasma reagin (RPR) or Venereal Disease Research Laboratory (VDRL) test Blood cultures, if patient is febrile (bacterial, mycobacterial, and fungal, as indicated) Testing for specific infections if suspected (eg, Bartonella or LGV) If a node is large, fixed, nontender, or otherwise worrisome, or if the diagnosis is unclear after initial evaluation, fine-needle aspiration (FNA) biopsy may provide a diagnosis. If FNA is nondiagnostic (falsenegative results are relatively common), obtain an open biopsy for definitive evaluation. Biopsy specimens should be sent for bacterial, mycobacterial, and fungal cultures; acid-fast staining for mycobacteria; and cytologic examination. If a node is large, inflamed, tender, or fluctuant, and a bacterial infection is suspected, consider initiating empiric antibiotic treatment and monitoring the patient over 1-2 weeks. If the node does not respond to antibiotic treatment or the patient becomes more symptomatic, arrange for FNA or open biopsy to establish the diagnosis.
Page 1 and 2:
Clinical Manual for Management of t
Page 3 and 4:
Table of Contents Clinical Manual f
Page 5 and 6:
Clinical Manual for Management of t
Page 7 and 8:
Preface—About this Manual | Clini
Page 9:
Previous Editions Atlanta Contribut
Page 12 and 13:
♦ ♦ ♦ ♦ ♦ | Clinical Manu
Page 14 and 15:
1-2 | Clinical Manual for Managemen
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 23 and 24:
Initial Physical Examination Backgr
Page 25 and 26:
Genitals/Rectum • Inspect the gen
Page 27 and 28:
Initial and Interim Laboratory and
Page 29 and 30:
Section 1—Testing and Assessment
Page 31:
Patient Education ♦ ♦ ♦ ♦ D
Page 34 and 35:
1-22 | Clinical Manual for Manageme
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 51 and 52:
Section 2—Health Maintenance and
Page 53:
References ♦ ♦ ♦ ♦ ♦ ♦
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 67 and 68:
Occupational Postexposure Prophylax
Page 69 and 70:
P: Plan Laboratory Testing Provide
Page 71 and 72:
For hepatitis C, no recommended pro
Page 73 and 74:
Page 75 and 76:
as hepatitis C or another sexually
Page 77 and 78:
for treatment is appropriate, and b
Page 79 and 80:
Page 81 and 82:
contact with the patient. Patients
Page 83 and 84:
tablet daily of trimethoprim-sulfam
Page 85 and 86:
Opportunistic Infection Prophylaxis
Page 87 and 88:
Discontinuing Primary Prophylaxis P
Page 89 and 90:
Latent Tuberculosis Background Late
Page 91 and 92:
INH may cause liver toxicity and it
Page 93:
Patient Education ♦ ♦ ♦ ♦
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 117 and 118:
Reducing Maternal-Infant HIV Transm
Page 119 and 120:
Some states require written informe
Page 121 and 122:
contraindicated during pregnancy be
Page 123 and 124:
Section 3—Antiretroviral Therapy
Page 125 and 126:
Nelfinavir (Viracept) Adequate drug
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133:
♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 165 and 166: Section 4—Complications of Antire
Page 167 and 168: ♦ ♦ ♦ Toronto General Hospita
Page 169 and 170: Adverse Reactions to HIV Medication
Page 171 and 172: ♦ ♦ ♦ ♦ ♦ Vital signs: No
Page 173 and 174: egimen, symptoms of fatigue could i
Page 175 and 176: Recreational Drugs and Antiretrovir
Page 177 and 178: Section 4—Complications of Antire
Page 179 and 180: LSD, Mescaline, Psilocin, and Methy
Page 181 and 182: Immune Reconstitution Syndrome Back
Page 183 and 184: A: Assessment In the appropriate cl
Page 185 and 186: ♦ ♦ ♦ ♦ ♦ Navas E, Martin
Page 187 and 188: 5-2 | Clinical Manual for Managemen
Page 195 and 196: 5-10 | Clinical Manual for Manageme
Page 202 and 203: Eye Problems Background The immunos
Page 204: of
Page 210 and 211: Fever Background Although fever may
Page 212 and 213: Headache Background Headache may ha
Page 216: Treatment Treatment will depend on
Page 222 and 223: Neurologic Symptoms Background The
Page 224 and 225: ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦
Page 226 and 227: Pulmonary Symptoms Background Short
Page 228: Treatment Once the diagnosis is mad
Page 238 and 239: Candidiasis, Oral and Esophageal Ba
Page 240: Maintenance therapy Use caution whe
Page 246 and 247: Cervical Dysplasia Background Cervi
Page 248: Patient Education ♦ ♦ ♦ ♦ P
Page 254 and 255: Cryptosporidiosis Background Crypto
Page 256: Patient Education ♦ ♦ ♦ ♦
Page 266 and 267:
Gonorrhea and Chlamydia Background
Page 268 and 269:
Treatment of Gonorrhea Treatment op
Page 270 and 271:
Hepatitis B Infection Background He
Page 272 and 273:
♦ ♦ ♦ ♦ ♦ Some patients t
Page 274 and 275:
Hepatitis C Infection Background He
Page 276 and 277:
pregnancy. Ribavirin is teratogenic
Page 278 and 279:
Herpes Simplex, Mucocutaneous Backg
Page 280:
References ♦ ♦ ♦ ♦ ♦ Cent
Page 283 and 284:
Page 285 and 286:
Page 288 and 289:
Kaposi Sarcoma Background Kaposi sa
Page 290 and 291:
Treatment Treatment of KS is not co
Page 292 and 293:
Molluscum Contagiosum Background Mo
Page 294 and 295:
Mycobacterium avium Complex Backgro
Page 296 and 297:
Table 1. Interactions between Rifab
Page 298 and 299:
Mycobacterium tuberculosis: Treatme
Page 300 and 301:
P: Plan Diagnostic Evaluation Durin
Page 302 and 303:
Table 1. Regimens for Treatment of
Page 304 and 305:
Rifabutin may be substituted for ri
Page 306:
Page 309 and 310:
Page 311 and 312:
Page 314 and 315:
Non-Hodgkin Lymphoma Background Non
Page 316:
Patient Education ♦ ♦ ♦ ♦ S
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
6-100| Clinical Manual for Manageme
Page 335 and 336:
6-102| Clinical Manual for Manageme
Page 338 and 339:
Toxoplasmosis Background Toxoplasma
Page 340 and 341:
♦ Atovaquone 1,500 mg orally twic
Page 342 and 343:
Linear Gingival Erythema Background
Page 344 and 345:
Background Necrotizing ulcerating p
Page 346 and 347:
Oral Health Background Examination
Page 348 and 349:
Maxillary Tori; Mandibular Tori S:
Page 350 and 351:
Periodontal Disease Background The
Page 352 and 353:
Oral Hairy Leukoplakia Background O
Page 354 and 355:
Oral Ulceration Background Oral ulc
Page 356 and 357:
Oral Warts Background Oral warts ar
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 369 and 370:
Anxiety Disorders Background Anxiet
Page 371:
Patient Education ♦ ♦ Behaviora
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 381 and 382:
Insomnia Background Insomnia is a c
Page 383 and 384:
Suicidal Ideation Background Transi
Page 385 and 386:
Section 8—Neuropsychiatric Disord
Page 387 and 388:
P: Plan ♦ ♦ ♦ ♦ ♦ Check t
Page 389 and 390:
Correctional Settings Background Ca
Page 391 and 392:
Adherence Adherence is one of the m
Page 393:
Karnofsky Performance Scale Backgro
Page 396 and 397:
Page 398 and 399:
Page 400:
show all

Clinical Manual for Management of the HIV-Infected ... - myCME.com

Create successful ePaper yourself

Delete template?

Save as template?